Nature Search

Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene

Karin Haack
Michael Linnebacher
Johannes Gebert
Research01 Oct 2000
Cancer Gene Therapy

Volume: 7, P: 1357-1364
Author Correction: Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids

Eva Blondeel
Sam Ernst
Olivier De Wever
Amendments and Corrections09 Jun 2025
Nature Protocols

P: 1
Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells

Yuru Shang
Xianbin Zhang
Michael Linnebacher
ResearchOpen Access09 Feb 2021
British Journal of Cancer

Volume: 124, P: 1411-1420
Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor

Jens Plaschke
Michael Linnebacher
Hans K Schackert
Research18 Jan 2006
European Journal of Human Genetics

Volume: 14, P: 561-566
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Precision oncology relies on model systems that reflect the genomic heterogeneity of human cancers. Here the authors characterize a panel of 151 colorectal cancer cell lines with respect to genetic mutations, expression profiles and drug sensitivity to identify new therapeutic targets.

Enzo Medico
Mariangela Russo
Alberto Bardelli
Research30 Apr 2015
Nature Communications

Volume: 6, P: 1-10
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies

The emergence of sub-clones that are resistant to targeted agents is a major therapeutic obstacle in oncology. Here, using colorectal cancer as a model system, the authors show that interfering with ancestral oncogenic events present in all subclones-like APC-WNT pathway alterations—can restrain the emergence of drug-resistant populations.

Mariangela Russo
Simona Lamba
Alberto Bardelli
ResearchOpen Access12 Jun 2018
Nature Communications

Volume: 9, P: 1-12
Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells

Sandra Schwarz
Zhaoran Su
Michael Linnebacher
ResearchOpen Access29 Jul 2024
npj Precision Oncology

Volume: 8, P: 1-10
Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids

The authors present a protocol for the self-assembly of single-cell suspensions into spheroids by the liquid overlay method, followed by a modular framework of orthogonal assays to phenotype spheroids both longitudinally and at an endpoint.

Eva Blondeel
Sam Ernst
Olivier De Wever
Protocols08 Apr 2025
Nature Protocols

Volume: 20, P: 2899-2941
PD-L1 is an activation-independent marker of brown adipocytes

Current approaches to visualise brown adipose tissue (BAT) rely primarily on markers that reflect its metabolic activity. Here, the authors show that PD-L1 is expressed on brown adipocytes, does not change upon BAT activation, and that BAT volume in mice can be measured by PET-CT with a radiolabeled anti-PD-L1 antibody.

Jessica R. Ingram
Michael Dougan
Hidde L. Ploegh
ResearchOpen Access21 Sept 2017
Nature Communications

Volume: 8, P: 1-10
NSG mice as hosts for oncological precision medicine

The severe immunodeficiency of NOD.Cg-Prkdc^scidIl2rg^tm1Wjl (NSG) mice, a widely used strain for generating patient-derived xenografts from primary tumors, impairs drug metabolism and reduces tolerability towards common cytostatic drugs. Consequently, dose finding and tolerance tests are strongly recommended prior to perform large-scale cancer precision medicine approaches.

Claudia Maletzki
Stephanie Bock
Michael Linnebacher
Research13 Aug 2019
Laboratory Investigation

Volume: 100, P: 27-37
Establishment and characterization of HROC69 – a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft

Florian Kuehn
Christina S. Mullins
Michael Linnebacher
ResearchOpen Access18 Apr 2016
Scientific Reports

Volume: 6, P: 1-10
CD5: from antiquated T cell marker to immunotherapy’s new hope

Sandra Schwarz
Michael Linnebacher
Research HighlightsOpen Access25 May 2023
Signal Transduction and Targeted Therapy

Volume: 8, P: 1-3
β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells

Oksana Voloshanenko
Uwe Schwartz
Michael Boutros
ResearchOpen Access16 Feb 2018
Scientific Reports

Volume: 8, P: 1-14
UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established tumorigenic pathway in human colorectal cancer

Sanam Sane
Rekha Srinivasan
Khosrow Rezvani
Research10 Apr 2023
Oncogene

Volume: 42, P: 1763-1776

Search

Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene

Author Correction: Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids

Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells

Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies

Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells

Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids

PD-L1 is an activation-independent marker of brown adipocytes

NSG mice as hosts for oncological precision medicine

Establishment and characterization of HROC69 – a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft

CD5: from antiquated T cell marker to immunotherapy’s new hope

β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells

UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established tumorigenic pathway in human colorectal cancer

Search

Quick links

Search

Filter By:

Search

Quick links